Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs Roen Rx

Two GLP-1 desks, one scoreboard. We put Trimi and Roen Rx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 327 · Grade C

Roen Rx

Visit Roen Rx Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 60 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Roen Rx a bad call — it's best for patients with insurance seeking brand-name glp-1 access with compounded fallback. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
32
Supply Reliability
89
75
Transparency
91
64
Access Breadth
89
56
Clinical Oversight
88
74
Track Record
84
73
TrimiBrief Score 89 · 60Roen Rx

Price, coverage & the tracker

TrimiRoen Rx
Brief Score89/100 (B+)60/100 (C)
Semaglutide$196/moFrom $151/mo (3-month plan, plus a separate fee, compounded)
Tirzepatide$296/moFrom $216/mo (medication billed separately, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Roen Rx: New to the tracker on 1 August 2026. The published line reads From $151/mo (3-month plan, plus a separate fee, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.